Literature DB >> 305409

Identity of a T-lymphocyte inhibitor with mouse immunoglobulin in the serum of tumour-bearing mice.

J G Levy, R McMaster, B Kelly, R B Whitney, D G Kilburn.   

Abstract

A component of the serum of tumour-bearing mice has been shown to be inhibitory to the immunological function of normal mouse T cells. This factor fractionates with monomeric immunoglobulin upon gel filtration. Studies were carried out utilizing goat antisera to the major immunoglobulin chains of mouse Ig (kappa, gamma, alpha and mu) mixed with the immunoglobulin-rich fraction of serum from normal mice and tumour bearers and passed through immunoadsorbent columns prepared with rabbit anti-goat immunoglobulin. Such studies showed that the inhibitory activity in tumour-bearing serum could be removed after treatment with anti-kappa, anti-gamma and anti-mu chain antisera but not by treatment with either anti-alpha chain or goat immunoglobulin. That the inhibitory activity of tumour-bearing immunoglobulin could be attributed to simple quantitative differences in the levels of IgM and IgG in the test samples was discounted by quantification of the amounts of immunoglobulins in normal and tumour-bearing sera.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 305409      PMCID: PMC1445475     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  15 in total

1.  Isolation of an immunosuppressive peptide fraction from the serum of cancer patients.

Authors:  R B Nimberg; A H Glasgow; J O Menzoian; M B Constantian; S R Cooperband; J A Mannick; K Schmid
Journal:  Cancer Res       Date:  1975-06       Impact factor: 12.701

2.  The effects of plasma from guinea pigs with tumor on PHA stimulated lymphocyte cultures.

Authors:  A A Vandenbark; D R Burger; P Finke; R M Vetto
Journal:  Cell Immunol       Date:  1976-03-15       Impact factor: 4.868

3.  Impaired responsiveness of lymphocytes and serum-inhibitory factors in patients with cancer.

Authors:  N Suciu-Foca; J Buda; J McManus; T Thiem; K Reemtsma
Journal:  Cancer Res       Date:  1973-10       Impact factor: 12.701

4.  Suppression of mitogen responses by serum from tumour-bearing mice.

Authors:  R B Whitney; J G Levy
Journal:  Eur J Cancer       Date:  1974-11       Impact factor: 9.162

5.  Suppression of mixed lymphocyte response in mice bearing primary tumors induced by murine sarcoma virus.

Authors:  B R Fernbach; H Kirchner; G D Bonnard; R B Herberman
Journal:  Transplantation       Date:  1976-05       Impact factor: 4.939

6.  Mode of action of immunosuppressive substances in sera of tumor-bearing mice.

Authors:  R B Whitney; J G Levy
Journal:  J Natl Cancer Inst       Date:  1975-12       Impact factor: 13.506

7.  A simple cell-suspension method for transplantation of V2 carcinoma.

Authors:  D M Berkowitz; L Alexander; N K Hollenberg
Journal:  J Natl Cancer Inst       Date:  1975-01       Impact factor: 13.506

8.  Characterization of a T-lymphocyte inhibitor in the serum of tumour-bearing mice.

Authors:  J G Levy; A G Smith; R B Whitney; R McMaster; D G Kilburn
Journal:  Immunology       Date:  1976-04       Impact factor: 7.397

9.  Effects of C-reactive protein on the lymphoid system. II. Inhibition of mixed lymphocyte reactivity and generation of cytotoxic lymphocytes.

Authors:  R F Mortensen; H Gewurz
Journal:  J Immunol       Date:  1976-05       Impact factor: 5.422

10.  Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor.

Authors:  W H Brooks; M G Netsky; D E Normansell; D A Horwitz
Journal:  J Exp Med       Date:  1972-12-01       Impact factor: 14.307

View more
  1 in total

1.  The use of the enzyme-linked immunosorbent assay (ELISA) for the detection and quantification of specific antibody from cell cultures.

Authors:  B S Kelly; J G Levy; L Sikora
Journal:  Immunology       Date:  1979-05       Impact factor: 7.397

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.